1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

A group of researchers from the University of Toronto in collaboration with the researchers from Agios Pharmaceuticals are focused on using CRISPR technology to screen six different genetically driven mouse cancer cell lines. It was foun...

Read More

---

Immune Checkpoint Inhibitors Combination to Control the Division of Cancer Cells in Bladder

Release Date: 24 November 2020

In the patients suffering from localized bladder cancer, immune checkpoint inhibitors in combination (tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1)) have shown better results as per the researchers who have conducted clinical res...

Read More

---

Next Generation ALK Inhibitors to Improve the Life of Patients having ALK-Positive NSCLC

Release Date: 24 November 2020

Certain safety profiles have been developed by combining eganelisib (IPI-549), a selective PI3K-andgamma; inhibitor, and nivolumab (Opdivo) in the patients suffering from head and neck squamous cell carcinoma. All the patients that were ...

Read More

---

Osimertinib to Overcome the Challenge of Developing Resistance in the Patients Suffering from NSCLC

Release Date: 24 November 2020

A novel study points out the significant benefits that is delivered through epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the patients suffering from non-small cell lung cancer patients and having EGFR-acti...

Read More

---

Sintilimab and Bevacizumab Injection to Deliver Promising Results in the Treatment of Advanced Heptacellular Cancer

Release Date: 24 November 2020

The combination of the drugs TYVYT^andreg; (sintilimab injection) and BYVASDA^andreg; (bevacizumab biosimilar injection, or IBI305) developed by Innovent Biologics is estimated to deliver promising results i...

Read More

---

Novel NRXN1 Therapeutic Target in ADC for Small Cell Lung Cancer

Release Date: 24 November 2020

A super novel study focuses on carrying a research with respect to the apoptosis assay of NRXN1-targeted antibody drug conjugate at IC50 dose with the help of growth inhibition curves. According to the researchers who are oriented toward...

Read More

---

Radioimmunotherapy Drug to Boost the Activity of Rituximab in Non-Hodgkin Lymphoma Patients

Release Date: 24 November 2020

Researchers have identified a novel radioimmunotherapy that is observed to effective in reversing resistance in case of lymphoma cancer. The novel radioimmunotherapy is effective in reversing resistance for the drug called as rituximab. ...

Read More

---

Novel Design of Nanotechnology to Deliver Promising Result in the Treatment of Cancer

Release Date: 24 November 2020

Novel study focused towards nanotechnology is estimated to deliver targeted as well as personalized vaccines into the cancer patients. As per the research conducted, the utilization of charged nanoscale metal-organic frameworks for gener...

Read More

---

CDK7 Inhibitors to Play Promising Role in Controlling Uncontrollable Division of Cancer Cells

Release Date: 23 November 2020

Protein is estimated to control the growth, proliferation as well as function of the tumor cells. A novel study indicates that a protein called as Cyclin Dependent Kinase 7 could be of broader biomedical application as it is responsible ...

Read More

---

Androgen Receptor Inhibitor to Provoke Better Survival Response in Metastatic Castration-Sensitive Prostate Cancer

Release Date: 23 November 2020

All the recent findings that have been conducted for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has completely re-shaped the entire treatment regimen available. The recent clinical trial study with respect t...

Read More

---

Lorlatinib to Deliver High Response Rate in the Lung Cancer Patients

Release Date: 23 November 2020

Reduced cancer size was observed in the patients suffering from anaplastic lymphoma when treated with (ALK)-inhibitor lorlatinib as well as reduced mortality rate in the patients was observed in the patients suffering from ALK-positive n...

Read More

---

Novel BRAF Inhibitor Drugs to Overcome Challenges of First Generation BRAF Inhibitor Drugs

Release Date: 23 November 2020

Patients having altered BRAF gene are now aligned towards getting a novel drug designed to treat the cancer. An important role of the BRAF gene is to inform the healthy cells to grow and transform into new cells but the gene is also responsible for the development of...

Read More

---

Dietary Supplements of Vitamin B3 to Improve the Efficacy of Immunotherapy Drugs

Release Date: 23 November 2020

Nutritional supplement such as nicotinamide riboside (NR) are believed to be increasing tumor infiltrating lymphocytes that have been exhausted against the microenvironment of the tumor. A novel study indicates that nicotinamide riboside...

Read More

---

Combination Drugs to Boost Clinical Outcomes for Advanced Kidney Cancer Treatment

Release Date: 23 November 2020

Combination of tyrosine kinase inhibitor drug with immunotherapy drug is estimated to increase the overall progression free survival as well as reduced death risk in the patients suffering from advanced kidney cancer. The patients enroll...

Read More

---

Biomarkers to Reveal Response Rate in Patients when Given Immune Checkpoint Inhibitor Drugs

Release Date: 22 November 2020

It is recorded for majority of the patients that immune checkpoint inhibitors are not as effective as observed for some of the patients. To end this, a group of researchers have identified some clinical markers that may help the research...

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |